We use our own and third party cookies to offer you our services, customize and analyze your browsing and show you advertising related to your preferences. By continuing to browse, we consider that you accept its use. You can change the settings and get more information in the
The future of breast cancer treatment involves offering a technique which is increasingly customised to the individual needs of each patient. There is not just one breast cancer, but rather there are at least four different types that require specific drugs and treatment choices. It is essential to identify each patient's type of breast cancer and then customise the treatment.
Genetic and biological analysis of the tumour means that hormonal therapy can be performed for longer while decreasing the length of chemotherapy, and it may even reduce the need for aggressive surgery or local treatment.
For that matter, biological information about tumours has a direct influence on the development of medicines that will target a specific characteristic of each tumour, such as the presence or absence of HER2 receptors, the presence or absence of oestrogen receptor mutations, whether the androgen receptor is expressed or unexpressed, etc. – information that will be used to adapt today's treatments.
The TILs is a program of personalised immunotherapy, which consists of manipulating and stimulating the patient's immune system so that it attacks its cancer.
Montserrat Muñoz MateuOncologistOncology Department
Published: 20 February 2018
Updated: 20 February 2018
The donations that can be done through this webpage are exclusively for the benefit of Hospital Clínic of Barcelona through Fundació Clínic per a la Recerca Biomèdica and not for BBVA Foundation, entity that collaborates with the project of PortalClínic.
Receive the latest updates related to this content.
Thank you for subscribing!
If this is the first time you subscribe you will receive a confirmation email, check your inbox
An error occurred and we were unable to send your data, please try again later.